Publication date: Jul 04, 2025
Coming into the study, participants had an average ON time without troublesome dyskinesia of 9. 3 (2. 62) hours and an ON time with troublesome dyskinesia of 0. 5 (1. 03) hours. From baseline to week 12, the longest duration of uninterrupted good ON time went from 4. 4 hours to 9. 6 hours (n = 65). Long-term safety and efficacy of apomorphine infusion in Parkinsons disease patients with persistent motor fluctuations: results of the open-label phase of the TOLEDO study. Early onset of efficacy during titration in US phase 3 open-label InfusON trial of apomorphine subcutaneous infusion for Parkinsons disease motor fluctuations. Despite the prevalence of dyskinesia, diary data showed that, overall, dyskinesia decreased throughout the 12-week study. Of these, 55. 4% reported much improved, 21. 5% were minimally improved, and 20. 0% rated themselves as very much improved. Kremens D, Hauser RA, Formella AE, Joshi M, Grall M. Improvement in Uninterrupted good ON time and reduction in OFF periods with CSAI treatment.
| Concepts | Keywords |
|---|---|
| Denmark | Apomorphine |
| Hauser | Daily |
| June | Day |
| Nct02006121 | Dyskinesia |
| Parkinsonism | Good |
| Hours | |
| Improved | |
| Infusion | |
| Participants | |
| Study | |
| Titration | |
| Trial | |
| Troublesome | |
| Week |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Caffeine |
| disease | MESH | Parkinson disease |
| pathway | KEGG | Parkinson disease |
| drug | DRUGBANK | Apomorphine |
| disease | MESH | Parkinsonism |
| disease | MESH | health status |
| disease | MESH | dyskinesia |
| drug | DRUGBANK | Amantadine |
| drug | DRUGBANK | Levodopa |
| disease | MESH | Movement Disorders |